Scoop: Green Val­ley's sea­weed-de­rived Alzheimer's drug, ap­proved in Chi­na, is halt­ed in PhI­II study

A Phase III study of a sea­weed-de­rived Alzheimer’s drug, con­di­tion­al­ly ap­proved in Chi­na in No­vem­ber 2019, has been halt­ed, five tri­al sites have con­firmed to End­points News.

Shang­hai-based Green Val­ley Phar­ma­ceu­ti­cals’ oligo­man­nate, or GV-971, was in a late-stage Alzheimer’s study dubbed “Green Mem­o­ry,” but the tri­al was halt­ed due to sup­ply chain is­sues, ac­cord­ing to four of the sites. One site said it was not sup­ply chain-re­lat­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER